Five Prime Therapeutics Inc (NASDAQ:FPRX)’s stock price was down 9.5% during trading on Monday . The company traded as low as $3.86 and last traded at $3.88, approximately 753,290 shares traded hands during trading. An increase of 106% from the average daily volume of 365,953 shares. The stock had previously closed at $4.28.
A number of equities research analysts recently commented on FPRX shares. ValuEngine upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Co lowered shares of Five Prime Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $35.00 to $10.00 in a report on Monday, June 3rd. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Guggenheim lowered shares of Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. Five Prime Therapeutics presently has a consensus rating of “Hold” and an average price target of $14.40.
The company has a quick ratio of 6.87, a current ratio of 6.87 and a debt-to-equity ratio of 0.23. The business’s fifty day moving average is $5.42 and its 200 day moving average is $8.02. The firm has a market capitalization of $156.14 million, a price-to-earnings ratio of -0.94 and a beta of 2.59.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.09). Five Prime Therapeutics had a negative return on equity of 62.13% and a negative net margin of 842.84%. The company had revenue of $3.33 million for the quarter, compared to analyst estimates of $5.53 million. Equities research analysts expect that Five Prime Therapeutics Inc will post -3.91 EPS for the current year.
Several large investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in shares of Five Prime Therapeutics by 2.3% during the second quarter. BlackRock Inc. now owns 2,882,588 shares of the biotechnology company’s stock worth $17,382,000 after acquiring an additional 63,634 shares during the period. Dimensional Fund Advisors LP grew its position in Five Prime Therapeutics by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,484,178 shares of the biotechnology company’s stock valued at $13,803,000 after purchasing an additional 71,001 shares in the last quarter. Man Group plc grew its position in Five Prime Therapeutics by 95.9% in the second quarter. Man Group plc now owns 1,160,411 shares of the biotechnology company’s stock valued at $6,997,000 after purchasing an additional 568,017 shares in the last quarter. Renaissance Technologies LLC grew its position in Five Prime Therapeutics by 86.5% in the second quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock valued at $6,930,000 after purchasing an additional 533,100 shares in the last quarter. Finally, Rock Springs Capital Management LP grew its position in Five Prime Therapeutics by 4.2% in the second quarter. Rock Springs Capital Management LP now owns 526,100 shares of the biotechnology company’s stock valued at $3,172,000 after purchasing an additional 21,100 shares in the last quarter. Institutional investors and hedge funds own 74.22% of the company’s stock.
Five Prime Therapeutics Company Profile (NASDAQ:FPRX)
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Recommended Story: Price-Sales Ratio
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.